Dear John,

 

Did you see the alarming recent report on real-world abortion data? Public insurance records show that mifepristone, the primary drug used in chemical abortions, seriously harms more than one in ten women who are prescribed it. You can help them. 

 

Tell the FDA to STOP THE HARM! CLICK HERE to tell your Senators, Congressman, HHS Secretary Kennedy and FDA Commissioner Dr. Makary to pull the dangerous abortion drugs. 

 

Commercial insurance data from 865,727 patients prescribed mifepristone between 2017 and 2023 shows 94,605 women suffered serious adverse events, including sepsis, infection, hemorrhage, or another serious adverse event within 45 days of taking the drug. That is 11% of women taking the drug. This real-world rate is twenty-two times greater than the rate claimed by the Food and Drug Administration (FDA) in approving mifepristone. 

 

The danger this drug poses to women cannot be overstated. Yet the FDA under the Obama and Biden administrations not only removed requirements to report these serious adverse health events, it also removed protections like requiring a doctor to examine the patient before prescribing the drug to rule out dangerous conditions like ectopic pregnancies. Most glaringly, the FDA also removed any requirement for the doctor to follow up on the patient’s condition after she ingests mifepristone. 

 

The FDA’s purpose is to promote the health and safety of Americans, not put them in the emergency room. Yet, the safety of women has been undermined by political whims. 

 

The evidence of mifepristone’s harm is clear. This tragic crisis must be stopped. Join us in calling on the FDA to give women the truth and STOP THE HARM by pulling this dangerous drug from the market. 

 

Click here to tell Congress, HHS Secretary Robert F. Kennedy, Jr., and FDA Commissioner Martin A. Makary, M.D. to act now! 

 

For life, 

John Mize

Chief Executive Officer

Americans United for Life

Ryan T. Anderson 

President 

Ethics & Public Policy Center 

 

 

Subscription Preferences